Cariprazine (Chengdu Kanghong) vs JX11502MA

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D3/D2 receptor (partial agonist) · full Schizophrenia pipeline

Cariprazine (Chengdu Kanghong)

Developed by Chengdu Kanghong Pharmaceutical

Phase 3 in Schizophreniasmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

JX11502MA

Developed by Zhejiang Jingxin Pharmaceutical Co., Ltd.

Phase 1/2 in Schizophreniasmall molecule
Weak signal

NCT06356389 · Phase 1/2 · completed

The study randomized 60 participants to JX11502MA or placebo and used double blinding, but the registry does not report whether the primary safety endpoint was met. Because the results are unavailable, the evidence supports only a limited assessment rather than a definitive conclusion. Its registered primary outcome on ClinicalTrials.gov is "Incidence of treatment-emergent adverse events (TEAEs)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Reported efficacy

The incidence rate of adverse reactions (Day(1)-Day(7)): JX11502MA was generally well tolerated at a single dose of 0.25 to 3 mg. The most common treatment-emergent adverse events were somnolence (56.3%), nausea (21.9%), dizziness (18.8%), vomiting (18.8%) and hiccups (18.8%).

Result source: NCT05233657

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCariprazine (Chengdu Kanghong)JX11502MA
PANSS total, change—Trial running · NCT06589817—Not reported
CGI-S, change—Trial running · NCT06589817—Not reported
PANSS response—Trial running · NCT06589817—Not reported
PSP, change—Trial running · NCT06589817—Not reported
Relapse (% of patients)—Trial running · NCT06589817—Not reported

PANSS total, change

Cariprazine (Chengdu Kanghong)
—Trial running · NCT06589817
JX11502MA
—Not reported

CGI-S, change

Cariprazine (Chengdu Kanghong)
—Trial running · NCT06589817
JX11502MA
—Not reported

PANSS response

Cariprazine (Chengdu Kanghong)
—Trial running · NCT06589817
JX11502MA
—Not reported

PSP, change

Cariprazine (Chengdu Kanghong)
—Trial running · NCT06589817
JX11502MA
—Not reported

Relapse (% of patients)

Cariprazine (Chengdu Kanghong)
—Trial running · NCT06589817
JX11502MA
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Cariprazine (Chengdu Kanghong): no structured comparison results are available for Schizophrenia.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

JX11502MA
JX11502MA was generally well tolerated at a single dose of 0.25 to 3 mg. The most common treatment-emergent adverse events were somnolence (56.3%), nausea (21.9%), dizziness (18.8%), vomiting (18.8%) and hiccups (18.8%). NCT05233657 · Phase 1 · design grade: moderate · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cariprazine (Chengdu Kanghong)'s landscape · JX11502MA's landscape